Plant Name: Farfugium japonicum
Taxonomic Information:
Plant ID: NPO13228
Plant Latin Name: Farfugium japonicum
Taxonomy Genus: Farfugium
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
186951
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMMedicinal Functions:
Antidote; Poultice
Geographical Distribution:
China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; CNR1; ADRA2A; CNR2; | |
| NMUR2; | |
| GAA; ACHE; | |
| MAPK1; | |
| RXRA; | |
| ALOX5; | |
| MMP2; | |
| POLB; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.121E-06 | 5.774E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.121E-06 | 5.774E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 2.121E-06 | 5.774E-03 | CNR1, CNR2 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 1.061E-06 | 5.774E-03 | CNR1, CNR2 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.061E-06 | 5.774E-03 | ADRA2A, ADRA2C |
| BP | GO:0032501; multicellular organismal process | GO:0019233; sensory perception of pain | 4.217E-06 | 7.063E-03 | CNR1, CNR2, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0051001; negative regulation of nitric-oxide synthase activity | 7.417E-06 | 1.066E-02 | CNR1, CNR2 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 9.886E-06 | 1.196E-02 | ADRA2A, ADRA2C |
| MF | Unclassified; | GO:0004871; signal transducer activity | 2.280E-05 | 2.027E-02 | ADRA2A, ADRA2C, CNR1, CNR2, MAPK1, NMUR2, RXRA |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 5.383E-05 | 3.781E-02 | ADRA2A, ADRA2C |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.596E-07 | 3.704E-05 | CNR2, CNR1, NMUR2, ADRA2C, ADRA2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.190E-04 | 4.559E-03 | MAPK1, ADRA2C, ADRA2A |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.328E-04 | 4.559E-03 | RXRA, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 4.992E-04 | 1.028E-02 | RXRA, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.671E-04 | 6.878E-03 | MMP2, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.495E-03 | 1.612E-02 | RXRA, MMP2, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.312E-03 | 1.612E-02 | MMP2, MAPK1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.978E-03 | 1.612E-02 | ALOX5, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.192E-03 | 1.612E-02 | ALOX5, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.192E-03 | 1.612E-02 | RXRA, MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
